Biosimilars

Biosimilars are biologic medical products that are highly similar to an approved reference biologic product, with no clinically meaningful differences in safety, purity, or potency. Because they are produced from living cells and are structurally complex, exact copies are not possible, unlike small-molecule generic drugs. Minor manufacturing differences may occur, but these are addressed through a rigorous comparability assessment demonstrating similarity to the reference product.

Regulatory agencies require a stepwise demonstration of biosimilarity through extensive analytical studies, nonclinical testing, and clinical trials that compare pharmacokinetics, efficacy, and safety. If similarity is established, the biosimilar may be approved for the same indications as the reference product, sometimes with extrapolation to other approved indications justified by mechanism of action and data. Distinct nonproprietary names with suffixes or other identifiers are used to distinguish biosimilars from the reference product in many jurisdictions.

Interchangeability and substitution vary by region. In the United States, an interchangeable biosimilar may be substituted for the reference product at the pharmacy level only after additional evidence showing that switching does not increase risk or decrease efficacy. In the European Union, substitution decisions are typically made by national authorities or individual member states, and there is no universal designation of interchangeability at the regulatory level.

Manufacturing complexity and immunogenicity are central considerations. Because biosimilars are produced in living systems, small process changes can alter identity or immunogenicity. Ongoing pharmacovigilance and postmarketing studies monitor safety. Biosimilars are expected to reduce treatment costs and increase access by promoting competition, though the extent of price reductions varies by market and product.